NEW YORK, Jan 4, 2026, 17:22 ET — Market closed
- Eli Lilly shares last closed up 0.5% at $1,080.36.
- CEO David Ricks is due to speak at the J.P. Morgan Healthcare Conference on Jan. 13.
- The company has scheduled its Q4 2025 earnings call for Feb. 4.
Eli Lilly shares rose 0.5% to $1,080.36 at Friday’s close, leaving the stock near the top of its recent range as U.S. markets remained shut over the weekend.
The next catalysts are close. Investors start the week positioning for the J.P. Morgan Healthcare Conference, the industry’s first major investor gathering of the year, where management teams often set the tone for guidance and pipeline priorities.
For Lilly, the bar is higher than most. The stock’s run has been powered by demand for its obesity and diabetes franchise, and traders tend to react quickly to any sign of tighter supply, slower prescription growth, or tougher reimbursement from insurers.
Lilly said its chair and CEO, David A. Ricks, will take part in a “fireside chat” — an interview-style session — on Tuesday, Jan. 13 at 5:15 p.m. ET. J.P. Morgan said its 44th annual healthcare conference runs Jan. 12-15 in San Francisco. PR Newswire
The company has also listed its Q4 2025 earnings call for Feb. 4 at 10:00 a.m. ET, a closer-in event that will put official numbers and 2026 expectations on the tape.
Lilly’s cardiometabolic business — including the GLP-1 class of medicines (drugs that mimic gut hormones to curb appetite and lower blood sugar) — remains the key battleground versus Novo Nordisk, which also sells blockbuster injectables in diabetes and obesity.
The stock’s latest move came as Wall Street began 2026 with a modestly firmer tone, with the Dow and S&P 500 edging up on Friday while the Nasdaq was little changed, according to a Reuters video report.
Technically, traders are likely to keep an eye on the $1,100 area as a near-term psychological level, with support around the low-$1,050s after the shares dipped to about $1,053 in the last session.
But the same concentration that has lifted the stock can cut the other way. Any hint of demand fatigue, a sharper-than-expected pricing pushback from payers, or competitive gains by rivals could pressure a valuation that many investors view as pricing in continued dominance in obesity drugs.
The next clear checkpoint is Jan. 13, when Ricks is scheduled to speak at the J.P. Morgan Healthcare Conference, with the Feb. 4 earnings call looming as the next market-moving event.
